New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027. SPVN06, a novel gene-agnostic adeno-associated virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results